Short Interest in Beyond Air, Inc. (NASDAQ:XAIR) Decreases By 24.4%

Beyond Air, Inc. (NASDAQ:XAIR) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 1,180,000 shares, a decrease of 24.4% from the November 30th total of 1,560,000 shares. Based on an average trading volume of 751,200 shares, the short-interest ratio is currently 1.6 days.

Institutional Trading of Beyond Air

An institutional investor recently bought a new position in Beyond Air stock. Soros Fund Management LLC bought a new stake in Beyond Air, Inc. (NASDAQ:XAIR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,476,626 shares of the company’s stock, valued at approximately $573,000. Soros Fund Management LLC owned approximately 3.13% of Beyond Air as of its most recent SEC filing. Institutional investors own 31.50% of the company’s stock.

Beyond Air Stock Performance

NASDAQ:XAIR opened at $0.44 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.38 and a current ratio of 5.76. Beyond Air has a fifty-two week low of $0.30 and a fifty-two week high of $2.20. The company has a 50 day simple moving average of $0.48 and a two-hundred day simple moving average of $0.52. The company has a market capitalization of $31.76 million, a PE ratio of -0.31 and a beta of -0.23.

Beyond Air (NASDAQ:XAIR) last issued its quarterly earnings results on Monday, November 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.19 million. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same period in the previous year, the firm earned ($0.51) earnings per share. Research analysts anticipate that Beyond Air will post -0.78 earnings per share for the current year.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.